University of Washington Researchers Develop Home Blood Clotting Clinical Laboratory Test That Uses a Smartphone and a Single Drop of Blood
UW scientists believe their at-home test could help more people on anticoagulants monitor their clotting levels and avoid blood clots In a proof-of-concept study,researchers at the University of Washington (UW) are developing a new smartphone-based technology/application designed to enable people on anticoagulants such as warfarin to monitor their clotting levels from the comfort of their […] The post University of Washington Researchers Develop Home Blood Clotting Clinical Laboratory Test That Uses a Smartphone and a Single Drop of Blood appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - May 9, 2022 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Digital Pathology Laboratory Instruments & Laboratory Equipment Laboratory Management and Operations Laboratory Pathology Laboratory Testing Precision Medicine anatomic pathology anticoagulants blood clot smartphone test clinical laborat Source Type: news
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
DOACs Comparable to Warfarin in CVT DOACs Comparable to Warfarin in CVT
DOACs were just as effective as warfarin in preventing future thrombotic events in patients with cerebral venous thrombosis stroke, with less major bleeding, in the retrospective ACTION-CVT study.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - February 15, 2022 Category: Intensive Care Tags: Cardiology News Source Type: news
Fewer Diabetes Complications With NOACs in Patients With AFib Fewer Diabetes Complications With NOACs in Patients With AFib
Patients with both diabetes and atrial fibrillation may derive greater benefits from non-vitamin K oral anticoagulants than from warfarin, a new study has found.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 15, 2022 Category: Endocrinology Tags: Family Medicine/Primary Care News Source Type: news
NOACs May Be Better Choice for Patients With A-Fib and DM
MONDAY, Feb. 14, 2022 -- For patients with atrial fibrillation (AF) and diabetes mellitus (DM), non-vitamin K antagonist oral anticoagulants (NOACs) are associated with lower risks for diabetes complications and mortality than warfarin, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2022 Category: Pharmaceuticals Source Type: news
Intracranial hemorrhage after head injury among older patients on anticoagulation seen in the emergency department: a population-based cohort study - Grewal K, Atzema CL, Austin PC, de Wit K, Sharma S, Mittmann N, Borgundvaag B, McLeod SL.
BACKGROUND: Intracranial hemorrhage (ICH) after head injury is a concern among older adult patients on anticoagulation. We evaluated the risk of ICH after an emergency department visit for head injury among patients 65 years and older taking warfarin or a ... (Source: SafetyLit)
Source: SafetyLit - January 21, 2022 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. clinicians slow to adopt new, safer direct oral anticoagulants
Despite evidence favoring direct oral anticoagulants over the drug Warfarin, adoption in U.S. clinical practice has been slow, a new Yale study finds. (Source: Yale Science and Health News)
Source: Yale Science and Health News - December 9, 2021 Category: Universities & Medical Training Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure.  These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Can Cannabis Help Your Gut?
When Joe Silverman developed Crohn’s disease at age 21, the symptoms started out mild. While the sight of blood in his stools initially freaked him out, what really bothered him was the frequent abdominal pain and bloating that occurred as his condition progressed to moderate and then severe. Dietary changes didn’t make a difference, so he began taking prescription oral anti-inflammatory drugs that are often used to treat certain bowel diseases, which alleviated but didn’t eliminate his discomfort. He started using prescription steroid suppositories to cope with flare-ups of the inflammatory bowel disease...
Source: TIME: Health - September 23, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Source Type: news
Renal Decline Slower With Rivaroxaban Than Warfarin in AF Patients Renal Decline Slower With Rivaroxaban Than Warfarin in AF Patients
The oral anticoagulant rivaroxaban is associated with both slower decline in kidney function and reduced risk of renal events compared with warfarin in atrial fibrillation patients.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Rates of Adverse Events Lower With Apixaban for A - Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2021 Category: Cancer & Oncology Tags: Cardiology, Internal Medicine, Oncology, Pharmacy, Geriatrics, Journal, Source Type: news
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
TUESDAY, July 20, 2021 -- For older adults with atrial fibrillation, apixaban is associated with lower rates of adverse events than warfarin across all frailty levels, according to a study published online July 20 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2021 Category: Pharmaceuticals Source Type: news